RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
287.80
-7.00 (-2.37%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close294.80
Open294.80
Bid287.80 x 400800
Ask288.90 x 100
Day's Range284.10 - 295.10
52 Week Range163.00 - 529.90
Volume173,525
Avg. Volume711,628
Market Cap816.451M
Beta (3Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-0.17
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
  • GlobeNewswire16 days ago

    RedHill Biopharma to Present at Three Conferences in April

    TEL-AVIV, Israel and RALEIGH, N.C., April 04, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswirelast month

    RedHill Biopharma to Present at the BIO-Europe Spring 2019 Conference

    TEL-AVIV, Israel and RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, senior vice president of business development and licensing, will present a corporate overview at the BIO-Europe Spring 2019 conference on Wednesday, March 27, 2019, at 9:45 a.m. CET at the Messe Wien Exhibition and Congress Center in Vienna, Austria. A copy of the presentation to be delivered by Mr. Frish will be available on the Company's website and may be viewed at: http://ir.redhillbio.com.

  • GlobeNewswirelast month

    RedHill Biopharma to Present at the 31st Annual ROTH Conference

    TEL-AVIV, Israel and RALEIGH, N.C., March 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on gastrointestinal (GI) diseases, today announced that Mr. Adi Frish, senior vice president of business development and licensing, will present a corporate overview at the 31st Annual ROTH Conference on Tuesday, March 19, 2019, at 1:00 p.m. PDT at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. The presentation will be broadcast live and available via replay for 30 days on the Company's website, http://ir.redhillbio.com/events.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces New European and Japanese Patents for Talicia®

    The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034 U.S. NDA for Talicia® on track for potential submission.

  • GlobeNewswire2 months ago

    RedHill Biopharma Provides Full-Year 2018 Financial Results and Operational Highlights

    TEL-AVIV, Israel and RALEIGH, N.C., Feb. 26, 2019 -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Host Full-Year 2018 Financial Results Conference Call on February 26, 2019

    TEL-AVIV, Israel and RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its full-year 2018 financial results and operational highlights on Tuesday, February 26, 2019. The Company will host a conference call on Tuesday, February 26, 2019 at 8:30 a.m. EST to review the financial results and business highlights.

  • GlobeNewswire2 months ago

    RedHill Biopharma Strengthens Management Team with Appointment of Rick D. Scruggs as Chief Operating Officer, U.S. Operations

    TEL-AVIV, Israel and RALEIGH, N.C., Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced that it has strengthened its commercial management team by appointing board member, Mr. Rick D. Scruggs as chief operating officer, U.S. operations. Mr. Scruggs is responsible for leading the Company’s U.S. commercial operations, currently promoting four GI products, and the preparations for the potential commercial launch of TALICIA® (RHB-105)1 for eradication of H. pylori infection, planned for the fourth quarter of 2019.

  • GlobeNewswire2 months ago

    RedHill Biopharma to Present at the 8th Annual SVB Leerink Healthcare Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal (GI) diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the 8th Annual SVB Leerink Healthcare Conference on Friday, March 1, 2019, at 9:30 a.m. EST, at the Lotte New York Palace, New York.

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection

    Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034NDA submission is expected in H1/2019, with eligibility for 6-month.

  • Reuters4 months ago

    Tel Aviv shares slide 5 pct in worst day since 2011

    Israeli stocks slid on Sunday, posting their worst daily performance in more than seven years in a broad selloff that followed declines on Wall Street late last week. The Tel Aviv 125 share index closed ...

  • GlobeNewswire4 months ago

    RedHill Biopharma Announces Closing of $20 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering for a total number of 2,857,143 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at a public offering price of $7.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 428,571 additional ADSs at the public offering price.

  • GlobeNewswire4 months ago

    RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire5 months ago

    RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund preparations for TALICIA® (H. pylori) commercial launch and commercialization activities, clinical development programs, including initiation of a pivotal Phase III study with RHB-204 for NTM, preparations for a second Phase III study with RHB-104 for Crohn’s disease and for acquisitions and general corporate purposes.

  • Reuters5 months ago

    RedHill Biopharma's antibiotic succeeds in late-stage study

    Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.

  • GlobeNewswire5 months ago

    RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection

    The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance.

  • GlobeNewswire5 months ago

    RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the BMO 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018, at 3:00 p.m. EST at the Mandarin Oriental Hotel, New York.

  • GlobeNewswire5 months ago

    RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases and cancer, today announced a poster presentation on YELIVA® (opaganib, ABC294640)1 for multiple myeloma at the upcoming EORTC-NCI-AACR Symposium2 on Molecular Targets and Cancer Therapeutics, on Friday, November 16th in Dublin.

  • GlobeNewswire5 months ago

    RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights

    Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA.

  • GlobeNewswire5 months ago

    RedHill Biopharma to Host Third Quarter 2018 Financial Results Conference Call on November 13, 2018

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it will report its third quarter 2018 financial results on Tuesday, November 13, 2018. The Company will host a conference call on Tuesday, November 13, 2018 at 8:30 a.m. EST to review the financial results and business highlights.